

## **PRESS INFORMATION**

### **Respiratory product opinion leaders meet in Lisbon**

**RDD® Europe 2009 brought together pulmonary and nasal drug delivery experts from 30 countries for a unique exchange of knowledge and expertise.**

(25 May, 2009) – From 19 to 22 May, 430 participants interested in pulmonary and nasal drug delivery attended the Respiratory Drug Delivery Europe 2009 symposium in Lisbon. During this intensive conference, leading experts presented the latest research and innovations in this dynamic field. The organisers were delighted by the high quality science presented and the unexpectedly large number of delegates who attended despite the current economic downturn. Feedback from participants also confirmed that RDD® Europe 2009 continues to enhance its reputation as one of the leading international scientific forums for academic, industrial and regulatory scientists involved in the research, development, delivery and commercialization of pulmonary and nasal drug products.

#### **Unique mix of innovation, new ideas and real news**

"RDD meetings continue to provide the highest quality in technical and scientific content covering our area of drug delivery. The unique mix of innovation and real news at this symposium is exceptional and rare. The organisers combine attention to detail with experience in the field to create opportunities for learning, debate and networking," said David Morton, Senior Lecturer at the Monash Institute of Pharmaceutical Sciences. A panel of invited international speakers addressed topics as diverse as the

'Expansion of Local and Systemic Therapies', 'Controlling Critical Quality Attributes during Manufacture', 'Powder Inhaler Design', 'Advances in Nasal Drug Delivery' and 'Assessing Critical Powder Properties'. Animated debate occurred around key questions associated with regulatory approval of inhalation devices.

### **Comprehensive and interactive program**

Expanded workshop sessions showcased research innovations, practical advice and current regulatory thinking. RDD delegates selected which of 12 interactive workshop demonstrations by technology and services providers they wanted to attend. Podium and workshop presentations were augmented by scientific posters and a technology exhibition which ran throughout the symposium and covered all aspects of regulatory science, formulation development, new research methods and advanced drug delivery technologies. A total of 44 ingredient, device and equipment designers, plus component and service suppliers from 11 countries presented their latest products and systems. A participant from the nebuliser workshop commented, "The workshop was very well constructed and provided an excellent overview regarding the regulatory situation, stimulating the required level of debate in the key areas."

### **Next Meeting, RDD 2010, Orlando, Florida**

RDD Europe 2009 was jointly organized by RDD Online<sup>®</sup>, Pfeiffer and Valois Pharma. Based on the success of the Lisbon meeting, this team will host RDD Europe 2011. "Over 700 participants, 100 poster presenters and 75 exhibitors are expected to converge on Orlando, April 25-29 for Respiratory Drug Delivery 2010. In this vibrant field new inventions and discoveries arise continuously, so there's plenty to keep us busy between European meetings," commented one member of the US organizing committee.

## **RDD Online**

RDD Online manages the organization of Respiratory Drug Delivery meetings in the US, and partners with Pfeiffer and Valois Pharma to run RDD meetings in Europe. Other RDD Online services available at [www.rddonline.com](http://www.rddonline.com) include providing scientific and technical publications, web-based training, and recruiting services of interest to companies active in pulmonary and nasal drug delivery.

## **Pfeiffer and Valois Pharma**

Valois Pharma, a division of Valois S.A.S., and Pfeiffer are world leaders in nasal and pulmonary drug delivery technologies with a broad range of innovative drug delivery devices, technologies and services. Pfeiffer and Valois S.A.S. are wholly owned subsidiaries of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

For further information visit [www.pfeiffer-group.com](http://www.pfeiffer-group.com) or [www.valoispharma.com](http://www.valoispharma.com)

Symposium Press Contact:

**Amanda Blair** - Tel. +41 41 740 37 55

[amanda.blair@abpr.ch](mailto:amanda.blair@abpr.ch)